A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) (NCT06785116)

🧪 Interventions in This Study

• Placebo (DRUG)
• Dapagliflozin 10mg Tab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\&D unit
2. Determined to be at least 23 and 0/7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery
3. Consents to participation and must understand/read/speak English with the ability to understand and willingness to sign a written informed consent in English
4. Diagnosed with a hypertensive pregnancy by either of the following criteria:
5. Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission
6. Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record
7. Antihypertensive" can be any medication taken for the purpose of blood pressure control per the medical record
8. A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery
9. Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.
10. Has two or more blood pressures ≥160/110 Millimeters of mercury (mmHg) at least 60 minutes apart
11. If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg/ml), participants are eligible to participate)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• University of Michigan — Ann Arbor, Michigan

📞 Contact the Study Coordinator

Phone: (734) 763-0295

Email: levijand@umich.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gestational Hypertension

• Angiogenic Factors in the Conservative Management of Gestational Hypertension — Panama City, Provincia de Panamá
• Vagal Stimulation Therapy and Preeclampsia — Guadalajara, Jalisco
• Postpartum CO Rehabilitation — Montreal, Quebec
• Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women — New York, New York

Explore by condition: All Gestational Hypertension clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.